A new UNC School of Medicine study of incretin-based medications, including newer medications such as semaglutide and tirzepatide that are widely prescribed for type 2 diabetes and obesity, finds they are associated with high rates of muscle loss relative to the amount of weight lost.
Continue Reading this article here
